行情

AIM

AIM

HEMISPHERX BIO
AMEX

实时行情|Nasdaq Last Sale

0.4627
-0.0099
-2.09%
休市 16:00 11/15 EST
开盘
0.4950
昨收
0.4726
最高
0.4950
最低
0.4627
成交量
19.16万
成交额
--
52周最高
14.81
52周最低
0.4500
市值
223.91万
市盈率(TTM)
-0.0557
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AIM 新闻

  • AIM ImmunoTech Provides Business Update for the Third Quarter of 2019
  • ACCESSWIRE.1天前
  • AIM ImmunoTech to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
  • ACCESSWIRE.10/23 11:30
  • Maxim Group Upgrades AIM ImmunoTech to Buy
  • Benzinga.10/10 11:58
  • AIM ImmunoTech upgraded to buy from hold, sets $2.00 stock price target at Maxim Group
  • marketwatch.com.10/10 07:31

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

AIM 简况

AIM ImmunoTech Inc., formerly Hemispherx Biopharma, Inc., is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.
展开

Webull提供AIM ImmunoTech Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。